Table 2. Comparison of the proportion of subjects with (“improved”^*) or without (“not improved” ^‡) reduction in pain frequency or drug consumption of ≥50% at the end of follow-up (responder rates), between IG and control group.

		Intervention Group	Control Group	RR (95%CI)	RR (95%CI)
		(N = 909)	(N = 972)	Crude	Adjusted§
Headache	Not Improved	672 (74%)	817 (84%)	1	1
	Improved	237 (26%)	155 (16%)	1.58 (1.28, 1.92)	1.58 (1.32, 1.87)
Neck/shoulder pain	Not Improved	636 (70%)	788 (81%)	1	1
	Improved	273 (30%)	184 (19%)	1.53 (1.27, 1.82)	1.53 (1.28, 1.82)
Headache and/or Neck/shoulder pain	Not Improved	590 (65%)	793 (82%)	1	1
	Improved	319 (35%)	179 (18%)	1.82 (1.52, 2.15)	1.83 (1.54, 2.14)
Analgesic Drug consumption	Not Improved	790 (87%)	874 (90%)	1	1
	Improved	119 (13%)	98 (10%)	1.45 (1.05, 1.97)	1.45 (1.03, 1.99)

*“Improved”: subjects with a baseline frequency of ≥4 days/month with pain (or drug consumption) that had a reduction in pain frequency or drug consumption of ≥50% at the end of follow-up.

^‡“Not improved”: includes subjects with ≥4 days/month with pain (or drug consumption) at the baseline with less than 50% of reduction in pain frequency or drug consumption at the end of follow-up, and those subjects that had a baseline frequency of less than 4 days with pain/drug consumption independently from their results.

^§adjusted by age, sex, neck/shoulder pain (when analyzing headache and analgesic drug consumption), headache (when analyzing neck/shoulder pain and analgesic drug consumption), education level, job activity and baseline value of each subject.